Arthrosurface hits the 20,000 implant milestone

Arthrosurface, Inc., announced that it has reached a milestone of having more than 20,000 patients, typically middle aged, treated with the various Arthrosurface cartilage resurfacing systems, with the early patients now 6 years post surgery, according to a company press release.

"Back in 2003, there was no accepted surgical ‘next step’ for those patients that had exhausted conservative [and] biological therapies such as drug injections & microfracture. With the passing of the 20,000-patient milestone and with more than 98% of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement," commented Steven Ek, COO.

“For very advanced disease in the older-aged patient, joint replacement still provides a good option. However, the baby-boomer population has been the silent sufferer. They have joint pain, limited mobility and all the signs of early articular cartilage damage. In my opinion, a well-accepted treatment for early disease in the boomer population does not exist. Having the Arthrosurface technology as an interim treatment has provided a great new option for these patients,” remarked Anthony Schepsis, MD, professor of orthopedic surgery at Boston University.

Arthrosurface’s inlay resurfacing technology uses a family of implants with different shapes and sizes to effectively recreate the patient's joint geometry with an intraoperative 3-D mapping instrument set, according to the release.